Diamond-Blackfan anemia is a rare congenital hematologic syndrome belonging to the group of ribosomopathies, characterized by selective failure of the erythroid lineage in the bone marrow. It typically manifests with severe macrocytic or normocytic anemia of early onset, often in the first months of life, associated with marked reticulocytopenia and, in most cases, preservation of the other hematopoietic cell lineages. A distinctive feature of the disease is the absence of signs of hemolysis or increased peripheral destruction of red blood cells despite profoundly impaired erythroid production.
Clinically, Diamond-Blackfan anemia is frequently accompanied by congenital malformations of variable degree, which may involve the craniofacial region, extremities, heart and urogenital system. Affected patients also have a documented increased risk of malignancies during life. In recent years, progress in understanding genetic and molecular mechanisms has allowed Diamond-Blackfan anemia to be defined as a paradigm of ribosomopathies, diseases caused by abnormalities in genes encoding ribosomal proteins, with selective impact on erythroid maturation and multisystem consequences.
Diamond-Blackfan anemia is caused by germline mutations affecting genes encoding ribosomal proteins, essential elements for the synthesis and correct assembly of cellular ribosomes. Most identified mutations show autosomal dominant transmission, but sporadic cases due to de novo mutations are also documented. The most frequently involved gene is RPS19, whose mutation accounts for about one quarter of all diagnosed cases. In addition to RPS19, numerous other mutations have been described in genes such as RPL5, RPL11, RPS24, RPS17 and others, contributing to a heterogeneous genetic picture that can nevertheless be traced back to a common defect in ribosomal biogenesis.
Mutations involving RPL5 and RPL11 are particularly relevant because of their association with more marked congenital malformations, especially craniofacial and skeletal malformations and cardiac defects. However, about 20-30% of patients do not have a known mutation among the genes identified so far, suggesting possible involvement of other ribosomal genes still to be discovered or of pathogenetic mechanisms not yet fully clarified.
Disease expression may vary widely even among individuals in the same family, with cases of severe anemia in the first months of life and others with more subtle, late-onset or even oligosymptomatic presentation. This variability is attributable both to the specific mutation type and to modifying genetic factors and environmental interactions that remain partly unknown.
In the vast majority of cases, Diamond-Blackfan anemia develops as a direct consequence of the genetic mutation, without acquired causes or environmental factors capable of inducing the disease in healthy subjects. However, some risk factors may modulate the severity of clinical presentation in patients who already carry the mutation. These include intercurrent viral infections (such as parvovirus B19), metabolic stress, surgical procedures and other conditions increasing erythropoietic demand, which may precipitate acute anemic crises or worsen reticulocytopenia.
It is important to emphasize that these factors are not primary causes of the disease, but may worsen the clinical picture in genetically predisposed subjects. In some cases, the anemia may appear transiently attenuated or worsened in relation to intercurrent events, contributing to the variability of the natural history of the disease.
The pathogenesis of Diamond-Blackfan anemia is closely linked to the effect of ribosomal gene mutations on the biology of hematopoietic stem cells, particularly erythroid precursors. Defective synthesis or assembly of ribosomal proteins causes reduced ribosomal biogenesis capacity and profound alteration of cellular protein synthesis. This imbalance mainly affects erythroblastic cells, whose rapid turnover and intense transcriptional activity make the erythroid lineage particularly vulnerable to functional ribosome depletion.
The central pathogenetic mechanism is activation of cellular response pathways to ribosomal damage. Deficiency of ribosomal proteins causes accumulation of incomplete or malformed ribosomal subunits, which in turn induce a state of “ribosomal stress” capable of activating the p53 pathway, the main regulator of the response to genomic and cellular damage. Hyperactivation of p53 causes cell-cycle arrest and selective apoptosis of erythroid progenitors, with progressive loss of the capacity for differentiation and maturation of red-lineage cells.
Unlike other forms of bone marrow failure, in Diamond-Blackfan anemia the lesion is almost limited to the erythroid series: the bone marrow appears normocellular or only mildly hypocellular, but with marked depletion of erythroid precursors, while granulocytic and megakaryocytic lineages are initially preserved. The peripheral smear shows marked anemia with severe reticulocytopenia, but without signs of hemolysis or ineffective hematopoiesis typical of thalassemias or myelodysplastic syndromes.
A distinctive aspect of Diamond-Blackfan pathophysiology is the presence of a compensatory increase in endogenous erythropoietin levels in response to chronic anemia. However, this increase is ineffective because erythroid progenitors are unable to respond adequately to the proliferative stimulus because of the underlying ribosomal defect.
Impairment of ribosomal biogenesis is not limited to the erythroid lineage: a substantial proportion of patients also show somatic developmental abnormalities, congenital malformations and increased genomic instability. This translates into long-term predisposition to malignancies, both hematologic and solid, through mechanisms including loss of the ability to maintain genome integrity, susceptibility to secondary mutations and inability to regulate cell proliferation.
Together, these mechanisms generate the typical picture of Diamond-Blackfan anemia: chronic macrocytic or normocytic reticulocytopenic anemia, without frank pancytopenia, often associated with signs of congenital malformations and, in the long term, a significantly increased cancer risk. Severity of clinical presentation and disease progression depend on the extent of the ribosomal defect, the specific mutation and modifying factors not yet fully clarified.
The onset and clinical evolution of Diamond-Blackfan anemia are highly heterogeneous, reflecting the variability of mutations and expression of the ribosomal defect. In most cases, the disease manifests in the first months of life, often within the first year, with symptoms attributable to chronic and progressive anemia. The classic clinical presentation includes variable cutaneous and mucosal pallor, worsening asthenia, poor growth and reduced exercise tolerance even in neonates and infants. Onset may be insidious and sometimes unrecognized, especially in less severe or partially compensated forms.
A typical element is profound reticulocytopenia, which contributes to the severity of the anemic picture and is accompanied by clinical signs of tissue hypoxia such as tachycardia, dyspnea and, in the most severe cases, high-output heart failure with congestion and profuse sweating. In infants, statural and weight growth delay and poor vitality may direct the diagnosis. Unlike other forms of chronic anemia, jaundice, signs of hemolysis and hemorrhagic manifestations are generally absent in Diamond-Blackfan anemia, whereas recurrent infections and spontaneous bleeding are rare because the other marrow lineages are relatively preserved.
In about 40-50% of patients, the disease is associated with extracardiac congenital malformations, whose presence may represent a fundamental diagnostic clue. The most common defects involve the craniofacial region (microcephaly, antimongoloid palpebral fissures, cleft palate), the hands (triphalangeal thumb, polydactyly, thumb hypo/aplasia), the heart (septal defects, aortic coarctation), the urogenital system (hypospadias, renal agenesis, duplications) and statural growth. In some cases, these abnormalities may be minimal or absent, whereas in others they heavily influence prognosis and quality of life.
On physical examination, in addition to cutaneous and mucosal pallor, functional systolic murmurs related to anemia, sometimes tachycardia and modest signs of heart failure in more severe pictures may be identified. Lymphadenopathy, significant hepatosplenomegaly or signs of marrow infiltration are not normally present, differentiating Diamond-Blackfan anemia from other pediatric hematologic diseases.
In rarer cases, especially at older ages or in the presence of aggravating factors, signs of broader bone marrow failure with leukopenia or thrombocytopenia may emerge, but this occurrence is the exception compared with the classic course. A clinically important element is the tendency, in a minority of patients, toward partial or complete spontaneous remissions, often temporary and followed by relapse even after many years.
History must always explore the presence of similar cases in the family, episodes of severe childhood anemia, associated malformations and history of malignancies, which are fundamental both for differential diagnosis and long-term risk assessment.
The diagnostic work-up of Diamond-Blackfan anemia is based on a rigorous clinical and laboratory assessment capable of recognizing the typical picture and excluding all possible alternative diagnoses of hyporegenerative anemia in childhood. The first element that should raise suspicion is the presence of macrocytic or normocytic anemia with early onset, often in the first six to twelve months of life, accompanied by marked reticulocytopenia and absence of signs of hemolysis or deficits in the other cell lineages. Accurate history and physical examination, with particular attention to congenital malformations, are decisive for correctly directing the diagnostic pathway.
The first laboratory step is the complete blood count, which documents isolated reduction of hemoglobin concentration, increased or normal mean corpuscular volume and reduced reticulocyte number. The other hematopoietic lineages are usually preserved, at least in the initial phase of the disease. The peripheral smear shows normocytic or macrocytic erythroid elements without significant anisopoikilocytosis and without dysplastic elements, with absence of schistocytes or spherocytes.
When clinical suspicion is well founded, bone marrow examination is performed and is fundamental for confirming the selective deficit of the erythroid lineage. Bone marrow aspirate and biopsy usually show normocellular or only mildly hypocellular marrow, with marked reduction or absence of mature erythroblasts, while granulocytic and megakaryocytic series are maintained. The presence of reduced numbers of immature erythroid cells, without signs of neoplastic infiltration, fibrosis or dysplasia, is highly suggestive of the diagnosis.
The differential diagnosis requires exclusion of all other causes of hyporegenerative anemia in childhood, such as transient erythroid aplasia (for example from parvovirus B19), pediatric myelodysplastic syndromes, severe deficiency forms (vitamin B12 or folate deficiency), Fanconi anemia and other congenital bone marrow failure syndromes. In this pathway, vitamin measurements, liver and kidney function tests, hemolysis indices and investigation of recent infections that may mimic the picture are essential.
Recognition of associated congenital malformations (craniofacial defects, limb malformations, cardiac or urogenital anomalies) is very helpful in directing the diagnosis toward Diamond-Blackfan anemia, especially when the hematologic picture is subtle. A positive family history of childhood anemia, similar malformations or malignancies reinforces diagnostic suspicion and may direct genetic counseling.
The definitive diagnosis is confirmed by molecular genetic analysis, with identification of a pathogenic mutation in one of the known ribosomal protein genes (RPS19, RPL5, RPL11, etc.). Genetic screening is recommended in all suspected cases, regardless of family history, because about half of cases may present as de novo mutations. In patients without identified mutations, the diagnosis remains probable in the presence of a typical clinical and laboratory picture.
Additional tests useful for better characterizing the disease and stratifying risk include evaluation of cardiac and renal function (to search for associated malformations), echocardiogram, renal ultrasound and, in more complex cases, hematologic assessment by flow cytometry or cytogenetic analysis. Careful clinical and laboratory monitoring over time is indispensable to assess disease course, response to therapies and occurrence of complications such as evolution toward myelodysplastic syndromes or development of malignancies.
Treatment of Diamond-Blackfan anemia is a clinical challenge requiring an individualized strategy based on patient age, anemia severity, presence of associated malformations and comorbidities. The primary objective is to ensure adequate tissue oxygenation, prevent complications related to severe chronic anemia and minimize adverse effects of therapies, both short- and long-term.
The first-line therapy in symptomatic children is corticosteroids, which can induce an effective erythropoietic response in about 70-80% of patients, at least initially. Prednisone is usually administered at moderate doses, followed by gradual reduction to the minimum effective dose needed to maintain acceptable hemoglobin levels. However, long-term maintenance of remission with corticosteroids carries significant side effects, including growth slowing, osteoporosis, hypertension, immunosuppression and metabolic abnormalities, which limit prolonged use, especially in small children.
In patients who do not respond to corticosteroids, develop intolerable side effects or lose response over time, regular packed red-cell transfusion becomes necessary to maintain adequate hemoglobin levels. This approach allows good symptom control but exposes to the risk of iron overload, with progressive accumulation of iron in vital organs. For this reason, early prophylaxis with iron chelators (such as deferasirox or deferoxamine) is essential in transfusion-dependent patients to prevent hepatic, cardiac and endocrine damage.
Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapy for Diamond-Blackfan anemia and is considered in patients with severe disease, early transfusion dependence and prolonged lack of response to corticosteroids. The best results are obtained in young patients without severe comorbidities and with an HLA-identical sibling donor. The most recent series report long-term survival above 75%, although the procedure remains burdened by risks of rejection, infections, immunologic complications (graft-versus-host disease) and toxicity related to the conditioning regimen, especially in subjects with organ malformations.
In recent years, new therapeutic options have been under investigation, such as the use of erythropoiesis agonists, selective inhibitors of the p53 pathway and targeted gene therapies, aimed at correcting the underlying molecular defect or enhancing survival of erythroid progenitors. Although data are still limited, these strategies represent a promising frontier for patients refractory to conventional therapies or not candidates for transplantation.
The prognosis of Diamond-Blackfan anemia has improved significantly in recent decades thanks to refinement of supportive therapies and transplant protocols. Nevertheless, long-term survival depends on multiple factors, including response to therapy, corticosteroid tolerance, cumulative transfusion burden and presence of major malformations or organ complications. The main negative prognostic factors are transfusion dependence, iron overload, therapy-related complications and development of malignancies, which constitute one of the main causes of mortality in adulthood.
A multidisciplinary hematologic follow-up is indispensable for long-term monitoring of marrow function, therapy tolerance, growth and development, organ function and onset of complications, with particular attention to prevention and prompt treatment of iron overload and early diagnosis of associated malignancies. Therapeutic choice must always be individualized and shared with the patient and family, with the aim of maximizing quality of life and minimizing long-term risks.
The complications of Diamond-Blackfan anemia are a central component of clinical management because they profoundly influence both prognosis and patient quality of life. These complications derive both from the chronic deficit of erythroid production and from the long-term effects of replacement and immunosuppressive therapies, as well as from the intrinsic predisposition linked to ribosomal dysfunction.
In the initial phase and during childhood, the greatest risk is represented by manifestations of severe anemia, with chronic tissue hypoxia that may lead to growth delay, reduced exercise tolerance, high-output heart failure in the most severe cases and difficulties in neurocognitive development. Maintaining adequate hemoglobin levels through periodic transfusions reduces the risk of irreversible organ damage, but inevitably entails other long-term complications.
Iron overload is one of the main problems in transfusion-dependent patients. Progressive iron accumulation, in the absence of a physiologic elimination pathway, leads to hepatic siderosis, cardiomyopathy, endocrine dysfunctions (hypogonadism, diabetes mellitus, hypothyroidism) and, in severe cases, organ failure. Iron toxicity requires regular and monitored chelation, whose impact on quality of life and therapeutic compliance may be relevant.
Although often effective in inducing the erythropoietic response, corticosteroids are associated with metabolic and systemic complications such as growth arrest, osteoporosis, hypertension, immunosuppression, mood changes and diabetes. In young children, duration of steroid therapy must be constantly balanced against the risks of long-term damage, which is why many patients need alternative strategies after the first years of life.
Allogeneic hematopoietic stem cell transplantation, although representing a potential definitive cure, carries risks of rejection, graft-versus-host disease (GVHD), opportunistic infections, toxicity from conditioning chemotherapy and, in patients with organ malformations, increased risk of perioperative complications. Careful candidate selection and specialized follow-up are essential to minimize transplant-related mortality.
One of the most feared long-term complications is predisposition to malignancies, both hematologic (such as myelodysplastic syndromes and acute leukemia) and solid (particularly osteosarcomas, colorectal tumors and urogenital malignancies). This risk reflects the genomic instability induced by the ribosomal defect and requires close clinical and laboratory monitoring, with early activation of diagnostic pathways in the presence of warning signs.
Other possible complications include congenital organ malformations that may condition prognosis independently of the hematologic picture, infectious complications related to immunosuppression (especially with prolonged steroid therapy or after transplantation), and psychological and social problems linked to chronic disease and therapeutic burden.
Effective management of complications of Diamond-Blackfan anemia requires a multidisciplinary approach and continuous proactive monitoring aimed at prevention, prompt treatment of adverse events and promotion of the best possible long-term quality of life.